

DISCLOSURES

The following have disclosed **no financial relationship** or interest with any proprietary entity producing healthcare goods or services.

Charlene Dunaway Altamirano, MD, PhD	Rebecca Jewel
Marc P. Breidenbaugh, MD	Pamela S. Lace, MA
Naomi Bryant, MS	Francesca Levi-Schaffer, PharmD, PhD
Melody C. Carter, MD	Monte Parsons
Martin D. Chapman, PhD	

Michael S. Blaiss, MD disclosed consultant, stock/ownership, advisory committee/board at Hippo Dx, Lanier Biotherapeutics; Nectar and Prollergy; consultant and advisory committee/board at Bryn Pharma, ALK and GSK; speakers bureau, faculty/peer reviewer, consultant and advisory committee/board at Sanofi and Regeneron Pharmaceuticals

Emily McGowan, MD, PhD disclosed advisory committee/board at Takeda; consultant at Regeneron Pharmaceuticals

Michael R. Nelson, MD, PhD disclosed industry funded research/investigator at Sanofi; industry funded research/investigator and stock/ownership at AstraZeneca; advisory committee/board at Regeneron and Kaleo

Thomas A. E. Platts-Mills, MD, PhD, FRS disclosed speakers bureau/faculty/peer reviewer and industry funded research/investigator at Phadia/Thermo-Fisher

Paul Turner, BSc, BM, BCh, FRCPC, FRACP, PhD disclosed consultant and advisory committee/board at Allergenis

Brian P. Vickery, MD disclosed consultant at Stellergenes Greer, Sanofi, Revolo, Moonlight, IgGenix; advisory committee/board at Parexel; consultant and stock/ownership at Novartis; advisory committee/board and industry funded research/investigator at Genentech

Andrew Wang, MD, PhD, AB disclosed consultant at The Column Group, Solell Bio and NGM Biopharmaceuticals

Jeffrey M. Wilson, MD, PhD disclosed Assay support from Thermo-Fisher/Phadia

DISCLOSURE OF FACULTY FINANCIAL AFFILIATIONS

The University of Virginia School of Medicine and School of Nursing as a Joint Accreditation Provider adhere to the ACCME ***Standards for Integrity and Independence in Accredited Continuing Education***, released in December 2020, as well as Commonwealth of Virginia statutes, University of Virginia policies and procedures, and associated federal and private regulations and guidelines. As the accredited provider for this CE/IPCE activity, we are responsible for ensuring that healthcare professionals have access to professional development activities that are based on best practices and scientific integrity that ultimately supports the care of patients and the public.

All individuals involved in the development and delivery of content for an accredited CE/IPCE activity are expected to disclose relevant financial relationships with ineligible companies occurring within the past 24 months (such as grants or research support, employee, consultant, stock holder, member of speakers bureau, etc.). The University of Virginia School of Medicine and School of Nursing employ appropriate mechanisms to resolve potential conflicts of interest and ensure the educational design reflects content validity, scientific rigor and balance for participants. Questions about specific strategies can be directed to the University of Virginia School of Medicine and School of Nursing of the University of Virginia, Charlottesville, Virginia.

The faculty, staff and planning committee engaged in the development of this CE/IPCE activity in the Joint Accreditation CE Office of the School of Medicine and School of Nursing have no financial affiliations to disclose.

DISCLOSURE OF DISCUSSION OF NON-FDA APPROVED USES FOR PHARMACEUTICAL PRODUCTS AND/OR MEDICAL DEVICES

As a Joint Accreditation provider, the University of Virginia School of Medicine and School of Nursing, requires that all faculty presenters identify and disclose any off-label or experimental uses for pharmaceutical and medical device products. It is recommended that each clinician fully review all the available data on new products or procedures prior to clinical use.
